Investigational drug · Phase 2
SCB-1022
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "SCB-1022"
First trial start
2025
Jun 18, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SCB-1022", any sponsor or status.
Conditions studied
As listed on its trial records.
- RSV Infection
- Human Metapneumovirus Infection
- Parainfluenza Infection
Approved drugs for the same conditions: Influenza · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "SCB-1022" as an intervention, largest first.
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older AdultsPivotal-lookingActive, not recruiting
Clover Biopharmaceuticals AUS PtyIndustry
NCT06984094 · 612 participants · Start Jun 18, 2025 · Primary completion Mar 2028
Drug: SCB-1019T; SCB-1022 and 2 more · For: RSV Infection; Human Metapneumovirus Infection; Parainfluenza Infection
Sites: Adelaide, Australia; Melbourne, Australia; Perth, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for RSV Infection
- RSVpreFRESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, PF-06928316Phase 38 trials
Pfizer · Respiratory Syncytial Virus (RSV), Lower Respiratory Tract Illness, Adult
- zelicapavirPhase 32 trials
Enanta Pharmaceuticals, Inc · RSV, RSV Infection, Respiratory Syncytial Virus (RSV)
- EDP-938Phase 21 trial
Enanta Pharmaceuticals, Inc · RSV Infection
- SCB-1019TPhase 21 trial
Clover Biopharmaceuticals AUS Pty · RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- SCB-1033Phase 21 trial
Clover Biopharmaceuticals AUS Pty · RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.